Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Huong Ngo

Psychiatry Santa Ana, CA Medical Doctor

NPI 1760491427 CMS profile 307429

401 W Civic Center Dr Ste 700, Santa Ana, CA 92701

Open in the dashboard

General payments

$7,143

278 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Huong Ngo of Santa Ana, CA is reported in the CMS Open Payments database as having received $7,143 across 278 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $871 35
2024 General $1,034 43
2023 General $852 38
2022 General $1,026 32
2021 General $644 16
2020 General $313 16
2019 General $2,402 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Huong Ngo
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Huong Ngo were reported at $871. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Huong Ngo Psychiatry median Middle half National median
2019 $2,402 $184 $59–$605 $163
2020 $313 $119 $36–$372 $114
2021 $644 $143 $43–$576 $132
2022 $1,026 $153 $50–$590 $149
2023 $852 $170 $56–$651 $160
2024 $1,034 $179 $57–$673 $164
2025 $871 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $1,312 65 payments
  2. Otsuka America Pharmaceutical, Inc. $1,274 51 payments
  3. Neurocrine Biosciences, Inc. $988 36 payments
  4. Sunovion Pharmaceuticals Inc. $931 31 payments
  5. Alkermes, Inc. $902 28 payments
  6. Janssen Pharmaceuticals, Inc $796 27 payments
  7. Indivior Inc. $461 20 payments
  8. Vanda Pharmaceuticals Inc. $187 9 payments
  9. E.R. Squibb & Sons, L.L.C. $158 6 payments
  10. Abbott Laboratories $55 1 payment
  11. Other $78 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,143 278 payments
Products named General payments · program years 2019–2025
  1. ABILIFY MAINTENA $1,110 48 payments
  2. LATUDA $931 31 payments
  3. INGREZZA $745 23 payments
  4. ARISTADA Cns $689 26 payments
  5. ARISTADA Cns $689 26 payments
  6. INVEGA SUSTENNA $574 25 payments
  7. INVEGA TRINZA $574 25 payments
  8. ARISTADA Cns $572 21 payments
  9. ARISTADA Cns $572 21 payments
  10. ARISTADA INITIO $540 20 payments
  11. Other $4,763 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

947

Median for Psychiatry & Neurology: 100

Drug cost

$393,013

Median for Psychiatry & Neurology: $2,986

Branded share of claims

21.4%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 13 $187,309
Invega Sustenna Paliperidone Palmitate Brand 31 $109,194
Austedo Xr Deutetrabenazine Brand 11 $54,787
Latuda Lurasidone Hcl Brand 13 $16,848
Abilify Aripiprazole Brand 12 $10,129
Aripiprazole Odt Aripiprazole Brand 13 $2,803
Clozapine Generic 22 $1,319
Aripiprazole Generic 35 $1,252
Olanzapine Generic 139 $1,141
Gabapentin Generic 40 $1,120

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $241
$241 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $229
$229 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $175
$175 24 —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $84
$84 12 —
PERSERIS
  • Indivior Inc. $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record